- AbbVie (NYSE:ABBV) announced on Friday that the U.S. Food and Drug Administration (FDA) approved its interleukin-23 (IL-23) inhibitor Skyrizi as a treatment for adults with moderately to severely active Crohn's disease.
- A collaboration between AbbVie (ABBV) and German pharmaceutical company Boehringer Ingelheim, Skyrizi was previously indicated in the U.S. for active psoriatic arthritis and certain patients with plaque psoriasis.
- Crohn's disease is characterized by inflammation within the gastrointestinal tract that can cause diarrhea and abdominal pain.
- The FDA decision was backed by two induction and one maintenance clinical trials, in which the treatment outperformed the placebo in terms of endoscopic response and clinical remission.
- Skyrizi, also known as risankizumab-rzaa in generic terms, generated $2.5B net revenue in the U.S. for AbbVie (ABBV) in 2021, indicating ~80% YoY growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments